Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]

X
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Acronyms KODIAC-07
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Jun 2016 Results of pooled analysis of three phase III studies (KODIAC 4, KODIAC 5 and KODIAC 7) published in the Advances in Therapy
    • 16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.
    • 10 Apr 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top